Message From Dana-Farber's Jennifer Brown, Md, Phd

Message from Dana-Farber's Jennifer Brown, MD, PhD

ASH23: Jennifer Brown, MD, PhD, discusses ALPINE trial | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Sharing the same mission : Dr. Jennifer Brown | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Jennifer Brown on Gauging Response in CLL

Dr. Jennifer Brown on Mutations and Targets in CLL

Jennifer Brown, MD, PhD, offers opinion on how zanubrutinib fits into the CLL treatment landscape

Dr. Jennifer Brown: Why Is It Important for You to Empower Patients?

Patient Empowerment Network

Jennifer Brown, MD, PhD, provides perspective on the side-effect profiles of next-gen BTK inhibitors

Jennifer Brown, MD, PhD, on BTK Inhibitors in CLL

Blood Cancers Today

Dr Jennifer Brown on the Role of Genomic Sequencing in CLL

Dr. Jennifer Brown on the Role of FCR in CLL

Jennifer Brown, MD, PhD, shares outcomes of Arm C of the SEQUOIA trial from ASH 2020

Dr. Jennifer Brown on Ibrutinib, Idelalisib, and Other Agents for CLL

Dr. Jennifer Brown on Idelalisib Plus Rituximab in CLL

Jennifer Brown, MD, PhD, considers the unmet needs in patients with CLL or SLL with del(17p)

Advances in Blood Cancers: Living with Chronic Lymphocytic Leukemia (CLL) - Treatment

Leukemia & Lymphoma Society

Jennifer M. Rosenbluth, MD, PhD, on breast cancer treatment | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Brown Gives an Overview of ABT-199 for the Treatment of CLL

Targeted Oncology

CHC 2018: DR. Jennifer Brown - Relapsed CLL in 2018

Dr. Jennifer Brown on RESONATE 2 Trial in CLL